scholarly journals Association of blood levels of homocysteine, vitamin B12, and serum cholesterol with age related macular degeneration in the elderly population of India

2021 ◽  
Vol 1 (3) ◽  
pp. 121-127
Author(s):  
Anushree Gupta
Keyword(s):  
Vitamin B12 ◽  
Macular Degeneration ◽  
Serum Cholesterol ◽  
Elderly Population ◽  
The Elderly ◽  
Age Related Macular Degeneration ◽  
Blood Levels ◽  
Age Related

Epidemiology Prevalence and Incidence in Dry-Form (Non-Neovascular) Age-Related Macular Degeneration

2017 ◽  
pp. 97-99
Keyword(s):  
Macular Degeneration ◽  
Elderly Population ◽  
The Elderly ◽  
Epidemiologic Studies ◽  
Age Related Macular Degeneration ◽  
Neovascular Amd ◽  
Age Related ◽  
Dry Amd ◽  
Degenerative Disorder ◽  
Definition Of

Age-related macular degeneration (AMD) is a degenerative disorder of the central retina and represents the leading cause of severe visual impairment in the elderly population of industrialized societies. It is known that it currently exists between 30 and 50 million people around the world and is estimated that will have doubled by the end of the coming decade. Several large epidemiologic studies have evaluated the prevalence of non-neovascular or so-called dry AMD. There is some variation in the prevalence of non-neovascular AMD depending on the exact definition of AMD. All of them report a higher prevalence of early AMD and an increasing prevalence with age. It is seen most in Caucasians and least in people with Africans and it is not related to gender.

scholarly journals Causes of low vision and use of optical aids in the elderly

2004 ◽  
Vol 59 (4) ◽  
pp. 157-160 ◽  
Author(s):  
Keila Monteiro de Carvalho ◽  
Gelse Beatriz Martins Monteiro ◽  
Cassiano Rodrigues Isaac ◽  
Lineu Oto Shiroma ◽  
Marcela Scabello Amaral
Keyword(s):  
Macular Degeneration ◽  
Elderly Population ◽  
Low Vision ◽  
The Elderly ◽  
Cross Sectional Study ◽  
Age Related Macular Degeneration ◽  
Rehabilitation Service ◽  
Visual Rehabilitation ◽  
Cross Sectional ◽  
Age Related

PURPOSE: To determine the causes of low vision in an elderly population attended by a university visual rehabilitation service and to check for the use of prescribed optical aids. METHOD: A cross-sectional study was carried out on patients aged 60 years or over attending for the first time a university low vision service in 2001. Ophthalmic reevaluation and interview were performed by means of a structured questionnaire in 2002. RESULTS: The sample comprised 50 subjects aged between 60 and 90 years. Severe low vision (<FONT FACE=Symbol><</FONT>20/200) was present in 68.0% of patients. The main cause of low vision was age-related macular degeneration (44.0%). Regarding literacy, 16.0% were illiterate and 72.0% had completed fundamental schooling. Thirty-one patients (62.0%) had been prescribed optical aids; 54.8% of these patients stated that they use them. A majority (70.6%) held a favorable opinion of these aids. CONCLUSIONS: The main cause of low vision was age-related macular degeneration. Approximately half of those receiving prescriptions reported actually using the aids in their daily activities. Making best use of residual vision in the elderly population with visual impairment is a priority, given the social context, if the independence necessary for enhanced quality of life is to be achieved.

scholarly journals Age-Related Choroidal Atrophy and Choroidal Neovascularization

2017 ◽  
pp. 336-339
Keyword(s):  
Optical Coherence Tomography ◽  
Macular Degeneration ◽  
Choroidal Neovascularization ◽  
Visual Function ◽  
Elderly Population ◽  
The Elderly ◽  
Age Related Macular Degeneration ◽  
Optical Coherence ◽  
Age Related

The choroid is a highly vascular, pigmented tissue located between the retina and sclera. The structure and thickness of choroid can be assessed by recently developed optical coherence tomography technologies. Age-related choroidal atrophy is a choroidal pathology that affects the elderly population and often accompanies and sometimes mimics age-related macular degeneration. Patients with age-related choroidal atrophy have a better visual function but have a higher risk of developing glaucoma.

scholarly journals Current understanding of Age-related macular degeneration

2020 ◽  
Vol 3 (2) ◽  
Author(s):  
Swathi Kanduri ◽  
Monica Liliana Acosta ◽  
Trevor Sherwin ◽  
Charles Ninian John McGhee ◽  
Colin R Green
Keyword(s):  
Macular Degeneration ◽  
Elderly Population ◽  
The Elderly ◽  
Developed Countries ◽  
Age Related Macular Degeneration ◽  
Current Understanding ◽  
Therapeutic Approaches ◽  
Age Related ◽  
The Developed Countries ◽  
Irreversible Blindness

Age-related macular degeneration (AMD) is the leading cause of irreversible blindness in the elderly population 50 years of age or older in the developed countries. This review discusses the traditional clinical and histopathological presentation of AMD, epidemiology and genetics component in relation to the current understanding of the vascular nature of the disease. Therapeutic approaches to treat the disease are also included in the review.

scholarly journals Present and Possible Therapies for Age-Related Macular Degeneration

2014 ◽  
Vol 2014 ◽  
pp. 1-7 ◽  
Author(s):  
Muhammad Khan ◽  
Ketan Agarwal ◽  
Mohamed Loutfi ◽  
Ahmed Kamal
Keyword(s):  
Macular Degeneration ◽  
Elderly Population ◽  
Treatment Options ◽  
The Elderly ◽  
Age Related Macular Degeneration ◽  
Common Cause ◽  
Age Related ◽  
Progressive Disorder ◽  
Additional Role

Age-related macular degeneration (AMD) is the most common cause of blindness in the elderly population worldwide and is defined as a chronic, progressive disorder characterized by changes occurring within the macula reflective of the ageing process. At present, the prevalence of AMD is currently rising and is estimated to increase by a third by 2020. Although our understanding of the several components underpinning the pathogenesis of this condition has increased significantly, the treatment options for this condition remain substantially limited. In this review, we outline the existing arsenal of therapies available for AMD and discuss the additional role of further novel therapies currently under investigation for this debilitating disease.

scholarly journals Future Therapies of Wet Age-Related Macular Degeneration

2015 ◽  
Vol 2015 ◽  
pp. 1-10 ◽  
Author(s):  
Makoto Ishikawa ◽  
Daisuke Jin ◽  
Yu Sawada ◽  
Sanae Abe ◽  
Takeshi Yoshitomi
Keyword(s):  
Macular Degeneration ◽  
Elderly Population ◽  
Therapeutic Targets ◽  
The Elderly ◽  
Age Related Macular Degeneration ◽  
Vegf Inhibitors ◽  
Ocular Neovascularization ◽  
Visual Outcomes ◽  
Duration Of Effect ◽  
Age Related

Age-related macular degeneration (AMD) is the leading cause of blindness in the elderly population, and the prevalence of the disease increases exponentially with every decade after the age of 50 years. While VEGF inhibitors are promising drugs for treating patients with ocular neovascularization, there are limitations to their potential for improving vision in AMD patients. Thus, future therapies are required to have the potential to improve visual outcomes. This paper will summarize the future strategies and therapeutic targets that are aimed at enhancing the efficacy and duration of effect of antiangiogenic strategies.

scholarly journals Impact of neovascular age-related macular degeneration: burden of patients receiving therapies in Japan

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Shigeru Honda ◽  
Yasuo Yanagi ◽  
Hideki Koizumi ◽  
Yirong Chen ◽  
Satoru Tanaka ◽  
...  
Keyword(s):  
Macular Degeneration ◽  
Productivity Loss ◽  
Work Productivity ◽  
The Elderly ◽  
Developed Countries ◽  
Age Related Macular Degeneration ◽  
Resource Utilisation ◽  
Total Work ◽  
Healthcare Resource Utilisation ◽  
Age Related

AbstractThe chronic eye disorder, neovascular age-related macular degeneration (nAMD), is a common cause of permanent vision impairment and blindness among the elderly in developed countries, including Japan. This study aimed to investigate the disease burden of nAMD patients under treatment, using data from the Japan National Health and Wellness surveys 2009–2014. Out of 147,272 respondents, 100 nAMD patients reported currently receiving treatment. Controls without nAMD were selected by 1:4 propensity score matching. Healthcare Resource Utilisation (HRU), Health-Related Quality of Life (HRQoL), and work productivity loss were compared between the groups. Regarding HRU, nAMD patients had significantly increased number of visits to any healthcare provider (HCP) (13.8 vs. 8.2), ophthalmologist (5.6 vs. 0.8), and other HCP (9.5 vs. 7.1) compared to controls after adjusting for confounding factors. Additionally, nAMD patients had reduced HRQoL and work productivity, i.e., reduced physical component summary (PCS) score (46.3 vs. 47.9), increased absenteeism (18.14% vs. 0.24%), presenteeism (23.89% vs. 12.44%), and total work productivity impairment (33.57% vs. 16.24%). The increased number of ophthalmologist visits were associated with decreased PCS score, increased presenteeism and total work productivity impairment. The current study highlighted substantial burden for nAMD patients, requiring further attention for future healthcare planning and treatment development.

scholarly journals Neovascular Macular Degeneration: A Review of Etiology, Risk Factors, and Recent Advances in Research and Therapy

2021 ◽  
Vol 22 (3) ◽  
pp. 1170
Author(s):  
Arunbalaji Pugazhendhi ◽  
Margaret Hubbell ◽  
Pooja Jairam ◽  
Balamurali Ambati
Keyword(s):  
Risk Factors ◽  
Macular Degeneration ◽  
Kinase Inhibitors ◽  
Rho Kinase ◽  
The Elderly ◽  
Age Related Macular Degeneration ◽  
Gene Therapies ◽  
Rho Kinase Inhibitors ◽  
Age Related ◽  
Endothelial Growth Factor

Neovascular age-related macular degeneration (exudative or wet AMD) is a prevalent, progressive retinal degenerative macular disease that is characterized by neovascularization of the choroid, mainly affecting the elderly population causing gradual vision impairment. Risk factors such as age, race, genetics, iris color, smoking, drinking, BMI, and diet all play a part in nvAMD’s progression, with anti-vascular endothelial growth factor (anti-VEGF) therapy being the mainstay of treatment. Current therapeutic advancements slow the progression of the disease but do not cure or reverse its course. Newer therapies such as gene therapies, Rho-kinase inhibitors, and levodopa offer potential new targets for treatment.

scholarly journals Introduction to the multi-author review on macular degeneration

2020 ◽  
Vol 77 (5) ◽  
pp. 779-780 ◽  
Author(s):  
Anu Kauppinen
Keyword(s):  
Macular Degeneration ◽  
Vision Loss ◽  
The Elderly ◽  
Developed Countries ◽  
Age Related Macular Degeneration ◽  
Age Related ◽  
Severe Vision Loss ◽  
Author Review ◽  
Dry Amd ◽  
Endothelial Growth Factor

AbstractProlonged life expectancies contribute to the increasing prevalence of age-related macular degeneration (AMD) that is already the leading cause of severe vision loss among the elderly in developed countries. In dry AMD, the disease culminates into vast retinal atrophy, whereas the wet form is characterized by retinal edema and sudden vision loss due to neovascularization originating from the choroid beneath the Bruch’s membrane. There is no treatment for dry AMD and despite intravitreal injections of anti-vascular endothelial growth factor (VEGF) that suppress the neovessel formation, also wet AMD needs new therapies to prevent the disease progression and to serve patients lacking of positive response to current medicines. Knowledge on disease mechanisms is a prerequisite for the drug development, which is hindered by the multifactorial nature of AMD. Numerous distinguished publications have revealed AMD mechanisms at the cellular and molecular level and in this multi-author review, we take a bit broader look at the topic with some novel aspects.

Sign in / Sign up

Export Citation Format

Share Document